EMA committee backs label change for GSK ’s Relvar Ellipta asthma therapy

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that a European Medicines Agency committee has backed an updated label for its once-daily asthma therapy, Relvar Ellipta.
If granted marketing authorization by the European Commission, the combination drug treatment will be approved for use in patients whose asthma is already controlled on an inhaled corticosteroid and a long-acting beta-2-agonist.
Get the full story at our sister site, Drug Delivery Business News.
The post EMA committee backs label change for GSK’s Relvar Ellipta asthma therapy appeared first on MassDevice.

Source: Mass Device - January 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news